一种抗精神病新药卡利拉嗪的受体作用模式介绍  

Receptor action model of a new antipsychotic drug: cariprazine

作　　者：周小东[1] 刘知源[1] 马锐[1] Zhou Xiaodong;Liu Zhiyuan;Ma Rui(Bethune International Peace Hospital of PLA,Shijiazhuang 050800,China)

机构地区：[1]解放军白求恩国际和平医院,河北石家庄050800

出　　处：《四川精神卫生》2019年第2期170-173,共4页Sichuan Mental Health

摘　　要：本文目的是系统阐述新型抗精神病药卡利拉嗪(cariprazine)的神经受体主要作用模式。抗精神病药物治疗是临床生物干预的重要手段之一,在一定程度上可以影响疾病预后的发展趋势。新型药物的开发始终是科研人员不懈的追求。卡利拉嗪是2015年美国FDA批准上市的新药,有望被引入国内,本文对其进行介绍便于临床医生参考。The purpose of this paper is to systematically illustrate the main action mode of the neuroreceptors of the new antipsychotic drug cariprazine. Antipsychotic drug therapy is one of the important means of clinical biological intervention, which can affect the development trend of disease prognosis to a certain extent. The development of new drugs has always been the unremitting pursuit of researchers. As a new drug approved by US FDA in 2015, caliprazine is expected to be introduced into China, so its introduction is convenient for clinical reference.

关 键 词：新型抗精神病药物 卡利拉嗪 受体作用模式 

分 类 号：R749[医药卫生—神经病学与精神病学]